On May 12, 2026, Professor Weiyue Lu, Director of the National Key Laboratory of Complex Drug Formulations for Overcoming Delivery Barriers and Professor at the School of Pharmacy, Fudan University, led a delegation on a visit to WinHealth Pharma’s Zhangjiang manufacturing site in Shanghai, where the two sides exchanged views on advances in drug formulation and delivery technologies, pathways from research to industrial application, and opportunities to further strengthen academic-industry collaboration.
During the visit, the delegation was briefed on WinHealth Pharma’s key development milestones, global footprint, and strategic priorities, including the company’s continued progress in key therapeutic areas and in building integrated capabilities across drug development, manufacturing and quality management, and commercialization. As a China-based comprehensive pharmaceutical company committed to linking global innovation resources, WinHealth Pharma continues to leverage international innovation to address patient needs in China and beyond, while translating clinically meaningful science into medicines and technologies that can improve patient care.
WinHealth Pharma’s Zhangjiang manufacturing site, located in the core area of Zhangjiang Pharma Valley in Shanghai, is a key component of the Company’s integrated development, manufacturing and supply platform. With a total site area of approximately 43,000 square meters, the site covers critical functions across drug development, manufacturing, quality control, warehousing and logistics, and supply chain management. Supported by GMP-compliant manufacturing systems, automated warehousing and digital operations management, the site strengthens WinHealth Pharma’s capabilities in high-quality manufacturing and reliable supply, while supporting the translation of scientific innovation into scalable therapeutic solutions for patients. It also provides a robust operational platform for the company to engage with global innovation and address patients’ evolving needs.
The National Key Laboratory of Complex Drug Formulations for Overcoming Delivery Barriers is a national research platform jointly reorganized by Yangtze River Pharmaceutical Group and Fudan University. The laboratory aims to become a leading platform in China, with international standards, for complex drug formulation research, technology development, and the translation of research advances into industrial and clinical applications.Across routes of administration such as oral delivery, intravenous injection and local injection, the laboratory undertakes research and development focused on addressing the physiological and pathological barriers encountered in drug delivery. This includes fundamental research on delivery barriers, formulation technology research, and the development of complex formulation products. Leveraging Fudan University’s academic strengths and Yangtze River Pharmaceutical Group’s industrial capabilities, the laboratory has continued to generate research advances in complex drug formulations and actively promote translational development and talent cultivation.
The two sides exchanged in-depth views on pathways for translating advances in complex drug formulations into industrial application, and identified areas of potential alignment for future collaboration in overcoming delivery barriers. Building on the laboratory’s scientific expertise in pharmaceutical formulation and drug delivery technologies, together with WinHealth Pharma’s integrated platform capabilities spanning drug development, manufacturing, quality management, and commercialization, both sides expressed interest in further leveraging their complementary strengths across the critical path from laboratory research to industrial application and clinical use. The dialogue underscored a shared commitment to advancing innovation, translation and clinical application in complex drug formulations, with the goal of bringing more clinically meaningful innovations to patients.
WinHealth Pharma will continue to foster open collaboration with academic institutions, research platforms and industry partners, with a focus on technology innovation, translational research and industrial application. By strengthening these collaborations, the Company aims to support the translation of pharmaceutical innovation into clinical value and contribute to the continued advancement of the biopharmaceutical industry.
About WinHealth Pharma
WinHealth Pharma is a China-based integrated pharmaceutical company with a core focus on kidney diseases and strategic expansion into hematology and other major therapeutic areas. It possesses comprehensive capabilities across the entire pharmaceutical value chain from research and development to manufacturing and commercialization. Guided by its “Patients-First” philosophy and the mission of “Advancing Health, Empowering Lives,” the company is dedicated to improving patients' quality of life through innovative therapies. By leveraging a multi-strategy-driven business model, WinHealth Pharma connects with global innovations to continuously build a diverse, differentiated, and highly competitive product portfolio. Anchoring a strong presence in China, the company is actively expanding into other Asian markets and key international regions, including Switzerland and Japan. WinHealth Pharma is committed to fostering an open and collaborative healthcare ecosystem, driving industry innovation to meet the evolving needs of patients worldwide. For more information, please visit www.winhealth.hk.